By doing a lazy Friday arvo chatgdp search current SoC for GBM after surgery is Temozolomide which is worth around $200m in sales. Patent expiry was in 2013 before which annual sales were approx $920 million. So one could take a 3-5x sales figure from that and discount what you think is appropriate for the trial stage. My hope and guess would be well north of $15m.
CHM's Future, page-6
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable